Rwanda vs Zimbabwe: Average cost of multi drug-resistant tuberculosis treatment
Rwanda
876 constant 2022 US$
in 2024
Zimbabwe
851 constant 2022 US$
in 2023
Rwanda rank
56th
Zimbabwe rank
57th
Average cost of multi drug-resistant tuberculosis treatment over time
- Rwanda
- Zimbabwe
How they compare
Rwanda currently reports 876 constant 2022 US$ against 851 constant 2022 US$ in Zimbabwe, a difference of 25 constant 2022 US$.
The two have swapped places 3 times across 7 shared years of data; in 2017 it was Zimbabwe ahead.
Rwanda ranks 56th and Zimbabwe ranks 57th of 92 countries.
Across the 2 decades both report, Rwanda averaged higher in 1 and Zimbabwe in 1.
Head to head by decade
| Decade | Rwanda | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,084 constant 2022 US$ | 1,672 constant 2022 US$ | 587.67 constant 2022 US$ | Zimbabwe |
| 2020s | 979.25 constant 2022 US$ | 696.25 constant 2022 US$ | 283 constant 2022 US$ | Rwanda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Rwanda or Zimbabwe?
- Rwanda, at 876 constant 2022 US$ against 851 constant 2022 US$ in Zimbabwe as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Rwanda and Zimbabwe?
- 25 constant 2022 US$, with Rwanda ahead.
- How many years of comparable data are there for Rwanda and Zimbabwe?
- 7 years are reported by both, from 2017 to 2023.
- How do Rwanda and Zimbabwe rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Rwanda ranks 56th and Zimbabwe ranks 57th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.